§ I · Value by Lifecycle

Strategic Intelligence That Compounds Over Time.

Transforming Market Access from a “Final Hurdle” into a “Foundational Strategy.”

The Challenge

The Billion-Dollar Disconnect

Too often, market access is treated as a downstream task—something to “fix” after the clinical data is locked. This disconnect creates billion-dollar value leaks: Phase III trials that miss HTA requirements, evidence gaps that trigger price cuts, and launch delays caused by avoidable objections.

With Tekmeria

Continuous Predictive Foresight

We provide a continuous thread of strategic intelligence that starts years before launch, ensuring that every development decision builds toward a commercially successful asset. Clinical strategy and market reality, unified from day one.

§ II · The Lifecycle Advantage

The Lifecycle Advantage

Phase 01 Pre-Clinical / Phase I

Early Strategy

Capital Efficiency & Early De-Risking

Before you commit massive resources to a pivotal program, you need to know if the asset has a viable path to reimbursement.

Comparator Landscape Scan: Identify the standard of care evolution to predict the correct comparator 5 years in advance.
Protocol Concept Review: Filter out trial designs that satisfy regulators but fail the “payer test.”

Fig. ii.i · Comparator Landscape Scan

Business Impact

Avoid investing in “dead-end” assets or indications with low pricing potential.

Phase 02 Phase II / III

Clinical Development

Asset Protection & Dual-Purpose Design

The most expensive mistake in pharma is running a flawless Phase III trial against the wrong comparator. We embed payer logic into the design phase.

HTA-Ready Trial Design: Ensure endpoints and patient subpopulations align with G-BA/HAS requirements, not just EMA/FDA.
Comparator Selection: Validate your control arm against the predicted future standard of care.

Fig. ii.ii · Dual-Purpose Design

Business Impact

Prevent the “20% Rejection Rate” caused by comparator mismatch and ensure your data supports a premium price.

Phase 03 Dossier Prep

Pre-Launch

Launch Excellence & Speed

Don’t wait for the HTA body to find the flaws in your dossier. We help you find them first.

Objection Anticipation: Predict the top 3-5 objections the HTA committee will raise and prepare robust counter-evidence.
Scenario Analysis: Model different submission strategies (e.g., broad vs. narrow label) to maximize the probability of a high “Added Benefit” rating.

Fig. ii.iii · Objection Anticipation

Business Impact

Reduce iterative rework and cut time-to-reimbursement by months.

Phase 04 Market Access

Launch

Revenue Maximization

When you enter price negotiations, data is your only leverage. We arm you with the numbers to defend your value.

Pricing Corridor Modeling: Establish a realistic, data-backed negotiation range based on analog assessments.
Negotiation Support: Simulate payer counter-arguments and equip your team with evidence-based rebuttals.

Fig. ii.iv · Pricing Corridor

Business Impact

Defend your price floor and secure the reimbursement status your innovation deserves.

§ III · The Bottom Line

The Bottom Line

End-to-End Alignment.

By engaging Tekmeria across the lifecycle, you don’t just get a report; you get a strategic partner that evolves with your asset. We turn the fragmented process of drug development into a cohesive journey toward commercial certainty.

View Our Solutions